Evidence map›Paper›PMID 41327461›Full record

ArticleGenome medicine2025

PathHDNN: a pathway hierarchical-informed deep neural network framework for predicting immunotherapy response and mechanism interpretation.

Xiangmei Li, Bingyue Pan, Yalan He, Ziyi Wang, Yujie Tang, Yongbao Zhang, Liqiang Wang, Junwei Han

Abstract read
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiangmei Li *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Bingyue Pan *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yalan He *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Ziyi WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yujie TangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yongbao ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Liqiang WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Junwei HanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. hanjunwei@ems.hrbmu.edu.cn.

Funding

National Natural Science Foundation of China 62372143Natural Science Foundation of Heilongjiang Province LH2019C042
6 · The paper itself

Abstract

backgroundImmunotherapy has revolutionized the treatment of cancer and tremendously prolonged the overall survival of patients; however, only parts of patients could derive durable clinical benefit from it. Predicting clinical responses to immunotherapy and interpreting the response mechanism remain major challenges.

methodsHere, we presented a pathway hierarchical-informed deep neural network (PathHDNN) framework to predict the therapeutic responses of cancer patients and identify key pathways associated with immunotherapy efficacy. PathHDNN was trained by encoding established biological pathway hierarchically knowledge into a neural network architecture through embedding the somatic mutations and copy number variations. During training, PathHDNN optimized only the edge weights connecting hierarchically related pathways, while maintaining the fixed network topology derived from biological pathway hierarchy, thereby preserving biological interpretability throughout the learning process.

resultsWe assessed PathHDNN on multiple immunotherapy cohorts and found it outperformed other state-of-the-art machine learning methods and established immunotherapy biomarkers. Moreover, through interpreting the trained model, PathHDNN effectively identified critical pathway features associated with the therapeutic response in melanoma cohort, particularly noting the critical roles of p53-mediated tumor suppression and JAK2-mediated immune regulation in the course of responsiveness to immunotherapy.

conclusionsIn conclusion, PathHDNN provided an effective pathway hierarchical-informed framework for accurately predicting patient responses to immunotherapy and identified key pathways yielding valuable insights into the biological mechanisms underlying treatment responses, which is essential for advancing precision medicine.

Indexed as

Deep LearningImmunotherapyNeoplasmsHumansImmune Checkpoint InhibitorsJanus Kinase 2Metabolic Networks and PathwaysMutationTreatment OutcomeTumor Suppressor Protein p53Immune Checkpoint InhibitorsJanus Kinase 2Tumor Suppressor Protein p53Deep neural networkImmune checkpoint inhibitorModel interpretabilityPathway hierarchically knowledgeSomatic mutations

Identifiers

PMID41327461
PMCPMC12729056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.